Pathalys Pharma
PrivateLast Round
Series B
Aug 20, 2024
Est. Valuation
$295M
Total Funding Raised
$255M
Company Overview
Pathalys Pharma is a biopharmaceutical company that develops advanced therapeutics to address unmet needs in the management of end-stage kidney disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathalys Pharma Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Pathalys Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 20, 2024 | ||||
| Early Funding | Jan 18, 2023 | ||||
| Seed | Mar 1, 2022 |
Pathalys Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Japan Post Investment Corporation | Series B |
| TCG Crossover | Series B |
| KB Investment | Series B |
| KB Investment | Series B |
| OrbiMed | Early Funding |
| Japan Post Bank Asset Management Co., Ltd. | Series B |
| The Carlyle Group | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2024
$105M round led by TCG Crossover.
Pathalys Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Pathalys Pharma's valuation, stock price, and market status.